Group 1 - The company Erkang Pharmaceutical (SZ 300267) held its 16th meeting of the 5th Board of Directors on October 29, 2025, to review documents including the proposal to amend the company's articles of association [1] - For the first half of 2025, the revenue composition of Erkang Pharmaceutical was as follows: 79.38% from the pharmaceutical industry, 18.57% from the new energy sector, and 2.05% from other businesses [1]

Core Viewpoint - Erkang Pharmaceutical announced the nomination of candidates for its sixth board of directors, including both non-independent and independent directors [1] Group 1: Board of Directors Nominations - The fifth board of directors approved the nomination of three non-independent director candidates: Shuai Fangwen, Shi Xiangyan, and Sun Qingrong [1] - The board also approved the nomination of three independent director candidates: Tan Xue, Liu Tiebian, and Wu Yong, with Tan Xue being a professional accountant [1]

Core Insights - The company reported a positive performance in Q3 2025, with a revenue of 1.006 billion yuan, representing a year-on-year growth of 17.81%, and a net profit of 39.5759 million yuan, showing a significant increase of 255.40% [1][3] - The company is expanding its overseas operations, with a $10 million investment in a comprehensive formulation production project in Tanzania, which is progressing as planned and is expected to meet GMP certification conditions by Q4 2025 [1][2] - The company is also investing $8 million in a new injection production project in Nigeria, which is part of its overall development strategy to enhance economic benefits and competitiveness [2] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.006 billion yuan, a 17.81% increase year-on-year [1] - The net profit for the same period was 39.5759 million yuan, reflecting a substantial growth of 255.40% compared to the previous year [1] Overseas Expansion - The company’s subsidiary in Tanzania is investing $10 million in a production project, with construction and equipment installation progressing on schedule [1] - The project aims to complete equipment debugging by Q4 2025 and is preparing for drug registration to facilitate market entry [1][2] - An additional investment of $8 million is planned for a new injection production project in Nigeria, expected to take 18 months to complete [2] Technological Development - The company’s subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is focusing on AI applications in rehabilitation robots and security, and has obtained various medical device operating qualifications [2] - The subsidiary has also expanded its intellectual property portfolio, completing new software copyrights and patent applications to enhance its competitive edge [2] Market Outlook - Market analysts view the company’s stable growth in Q3 2025 as a result of solid progress in industrial breakthroughs and technology development, which supports its future stability [3] - The collaborative advancement across multiple business lines is seen as a strong foundation for the company’s ongoing development [3]

Core Insights - The company reported a positive operational performance for the third quarter of 2025, achieving a revenue of 1.006 billion yuan, a year-on-year increase of 17.81%, and a net profit of 39.5759 million yuan, with a significant growth of 255.40% compared to the previous year [1][3] Group 1: Financial Performance - The company achieved a revenue of 1.006 billion yuan in the first three quarters of 2025, marking a 17.81% year-on-year growth [1] - The net profit for the same period reached 39.5759 million yuan, reflecting a substantial increase of 255.40% year-on-year [1] Group 2: Overseas Expansion - The company invested 10 million USD in a comprehensive formulation production project in Tanzania, which is progressing as planned with purification engineering and equipment installation [1] - The project is expected to complete equipment debugging by the fourth quarter of 2025 and is preparing for drug registration to meet regulatory requirements [1] Group 3: Technological Development - The company's subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., made advancements in AI technology applications, focusing on rehabilitation robots and security fields [2] - The subsidiary obtained operating qualifications for various medical devices, enhancing compliance for market expansion [2] - The company completed additional intellectual property filings, including 3 software copyrights and 2 invention patents, strengthening its technology barrier and market competitiveness [2] Group 4: New Projects - The company announced an investment of 8 million USD to establish an injection production project in Nigeria, with a construction period of 18 months [2] - This investment aligns with the company's overall development strategy and aims to expand its business reach and enhance economic benefits [2]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with revenue reaching 1.006 billion and a net profit of 39.5759 million, marking year-on-year growth of 17.81% and 255.40% respectively [1][2] Group 1: Financial Performance - The company achieved a revenue of 1.006 billion, reflecting a year-on-year growth of 17.81% [1] - The net profit for the same period was 39.5759 million, with a substantial increase of 255.40% compared to the previous year [1] Group 2: Overseas Expansion - The company is investing 10 million in a comprehensive formulation production project in Tanzania, which is progressing as planned and is expected to complete equipment debugging by the fourth quarter of 2025 [1] - An additional investment of 8 million is planned for a new injection production project in Nigeria, with an expected construction period of 18 months [2] Group 3: Research and Development - The company's subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is conducting market research and business development in AI technology applications, achieving qualifications for various medical devices [1] - The company has completed the documentation for 3 new software copyrights and 2 invention patents, with one patent application receiving preliminary approval [1]

湖南尔康制药股份有限公司 关联交易管理制度 第一章 总则 第一条 为进一步加强湖南尔康制药股份有限公司（以下简称"本公司"或 "公司"）关联交易管理，明确管理职责和分工，维护公司所有股东的合法利益， 保证公司与关联方之间的关联交易符合公平、公正、公开的原则，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《深圳证券交易所创业板股票上 市规则》（以下简称"《上市规则》"）、《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引 第7号——交易与关联交易》《企业会计准则-关联方关系及其交易的披露》等相 关法律、法规、规范性文件的要求以及《湖南尔康制药股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，制订本制度。 第二条 公司的关联交易应遵循以下基本原则： （一）诚实信用的原则； （二）不损害公司及非关联股东合法权益的原则； （三）关联股东及董事回避原则； （四）关联交易遵循市场公正、公平、公开的原则。关联交易的价格或收 费原则上不偏离市场独立第三方的标准，对于难以比较市场价格或定价受到限 制的关联交易，通过合同明确有关成本和利润的标准。 （ ...

湖南尔康制药股份有限公司 对外投资管理办法 第一章 总则 第一条 为规范湖南尔康制药股份有限公司（以下简称"公司"）对外投资 行为，降低对外投资的风险，提高投资效益，合理、有效的使用资金，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范 运作》等国家法律、法规、规范性文件和《湖南尔康制药股份有限公司章程》（以 下简称"公司章程"）的有关规定，结合公司实际情况，制定本办法。 （八）持有至到期投资； （二）收购、出售、置换其他公司股权； （三）增加、减少对外权益性投资； （四）股票投资、债券投资； （五）委托理财； （六）委托贷款； （七）投资交易性金融资产、可供出售金融资产； （九）其他对外投资。 本办法所指"交易"特指对外投资事项。 第五条 公司股东会、董事会、总经理办公会为公司对外投资的决策机构， 各自在其权限范围内， 对公司的对外投资做出决策。 公司对外投资的审批权限 具体为： （一）投资金额未达到董事会审批标准的对外投资项目，由公司总经理办公 会进行论证后经董事长批准执行，并及时报公司董事会备案 ...

湖南尔康制药股份有限公司 董事会议事规则 第一章 总则 第一条 为进一步规范湖南尔康制药股份有限公司（以下简称"公司"）董事 会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司治理准则》、《深圳证券交易所创业板股票上市规则》等相 关法律法规以及《湖南尔康制药股份有限公司章程》（以下简称"公司章程"） 的相关规定，公司制订本规则。 第二条 董事会对股东会负责，并依据国家有关法律、法规和公司章程行使 职权。 第三条 董事会由7名董事组成，设董事长1人，独立董事3人、职工代表董 事1人。独立董事中应至少包括一名会计专业人士。 第四条 董事会下设证券部，处理董事会日常事务。董事会秘书兼任证券部 负责人，保管董事会印章，董事会秘书可以指定证券事务代表等有关人员协助其 处理日常事务。 第二章 董事会职权 第五条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （十一）制订公司章程的修改方案； （十二）管理公司信息披露事项； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订 ...

重大投资及财务决策制度 第一章 总则 第一条 为规范湖南尔康制药股份有限公司（以下简称"公司"）经营决策 管理，明确公司重大投资及财务决策的批准权限与批准程序，根据《中华人民共 和国公司法》《深圳证券交易所创业板股票上市规则》等法律法规及《湖南尔康 制药股份有限公司章程》（以下简称"公司章程"）的规定，特制定本制度。 第二条 本制度所称重大投资包括但不限于： 除担保以外的项目投资；股权 投资（包括设立新企业、股权收购、增资扩股）；证券投资（包括新股配售、申 购、证券回购、股票及其衍生产品二级市场投资、债券投资等）；风险投资；委 托理财；融资贷款；租赁经营；资产处置（包括购买、出售、置换资产、资产抵 押）等事项。 第二章 重大投资决策的程序和规则 第三条 公司发生本制度第二条所述的交易事项达到下列标准之一的，应当 经公司董事会审议通过，并及时披露： 1、交易涉及的资产总额占公司最近一期经审计总资产的 10%以上，该交易 涉及的资产总额同时存在账面值和评估值的，以较高者作为计算依据； 湖南尔康制药股份有限公司 2、交易标的（如股权）在最近一个会计年度相关的营业收入占公司最近一 个会计年度经审计营业收入的 10%以 ...

湖南尔康制药股份有限公司 股东会议事规则 第一章 总则 （四）董事会认为必要时； （五）审计委员会提议召开时； （六）《公司章程》规定的其他情形。 公司在上述期限内不能召开股东会的，应当报告中国证券监督管理委员会湖 南监管局（以下简称"湖南省证监局"）和深圳证券交易所，说明原因并公告。 第二条 公司应当严格按照法律、行政法规、《股东会规则》、《公司章程》 及本规则的相关规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应 当勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开 1 次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现下列 情形之一的，公司在事实发生之日起 2 个月以内召开临时股东会： （一）董事人数不足《公司法》规定人数或《公司章程》所定人数的 2/3 时； （二）公司未弥补的亏损达股本总额 1/3 时； （三）单独或者合计持有公司 10%以上股份的股东书面请求时； 第一条 为规范湖南尔康制药股 ...